Abstract
Immunophenotyping by flow cytometry is an important component in the diagnostic evaluation of patients with acute lymphoblastic leukemia. This technique further permits the detection of minimal residual disease after therapy, a robust prognostic factor that may guide individualized treatment. We describe here laboratory methods for both the initial characterization of lymphoblasts at diagnosis, and the detection of rare leukemic lymphoblasts after treatment. In addition to antibody combinations suitable for diagnosis and detection of minimal residual disease, we describe procedures for peripheral blood and bone marrow sample preparation, procedures for labeling of cell-surface and intracellular proteins with fluorochrome-conjugated antibodies, and approaches to analysis of immunophenotypic data.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Swerdlow SH, Campo E, Harris NL et al (2017) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon
Borowitz MJ, DiGiuseppe JA (2014) Acute lymphoblastic leukemia/lymphoblastic lymphoma. In: Orazi A, Weiss LM, Foucar K et al (eds) Knowles’ neoplastic hematopathology. Lippincott Williams & Wilkins, Philadelphia, pp 1019–1029
DiGiuseppe JA (2016) Acute lymphoblastic leukemia/lymphoma: diagnosis and minimal residual disease detection by flow cytometric immunophenotyping. In: Detrick B, Hamilton R, Schmitz J (eds) Manual of molecular and clinical laboratory immunology, 8th edn. ASM Press, Washington, D.C., pp 207–216
Wood B, Soma L (2016) Acute myeloid leukemia: diagnosis and minimal residual disease detection by flow cytometry. In: Detrick B, Schmitz J, Hamilton RG (eds) Manual of molecular and clinical laboratory immunology, 8th edn. ASM Press, Washington, D.C.
Borowitz MJ, Bene M-C, Harris NL et al (2017) Acute leukaemias of ambiguous lineage. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon, pp 180–187
Wood BL (2016) Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. Cytometry B Clin Cytom 90:47–53
Gaipa G, Basso G, Biondi A et al (2013) Detection of minimal residual disease in pediatric acute lymphoblastic leukemia. Cytometry B Clin Cytom 84:359–369
Borowitz MJ, Devidas M, Hunger SP et al (2008) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's oncology group study. Blood 111:5477–5485
Wood B (2004) Multicolor immunophenotyping: human immune system hematopoiesis. In: Darzynkiewicz Z, Roederer M, Tanke HJ (eds) Cytometry. New developments, Methods in cell biology, vol 75, 4th edn. Elsevier, San Diego, CA, pp 559–576
Wood B (2006) 9-color and 10-color flow cytometry in the clinical laboratory. Arch Pathol Lab Med 130:680–690
Keeney M, Wood BL, Hedley BD et al (2017) A QA program for MRD testing demonstrates that systematic education can reduce discordance among experienced interpreters. Cytometry B Clin Cytom 94:239–249
DiGiuseppe J, Tadmor MD, Pe’er D (2015) Detection of minimal residual disease in B lymphoblastic leukemia using viSNE. Cytometry B Clin Cytom 88B:294–304
Gaipa G, Basso G, Aliprandi S et al (2008) Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells. Cytometry B Clin Cytom 74:150–155
Roshal M, Fromm JR, Winter S et al (2010) Immaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: implications for minimal residual disease detection. Cytometery B Clin Cytom 78:139–146
McKenna RW, Washington LT, Aquino DB et al (2001) Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood 98:2498–2507
Kantarjian H, Stein A, Gokbuget N et al (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376:836–847
Park JH, Riviere I, Gonen M et al (2018) Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378:449–459
Cherian S, Miller V, McCullouch V et al (2018) A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy. Cytometery B Clin Cytom 94B:112–120
DiGiuseppe JA, Fuller SG, Borowitz MJ (2009) Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection. Cytometry B Clin Cytom 76:150–155
Shinoda-Matsuoka H, DiGiuseppe JA (2009) Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: efficiency of minimal residual disease (MRD) detection by flow cytometric immunophenotyping compared with commonly used markers. Mod Pathol 89:388A
Acknowledgments
The authors gratefully acknowledge Dr. Brent Wood, University of Washington, Seattle, for his generous gift of WoodList 2.7.8 software.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
DiGiuseppe, J.A., Cardinali, J.L. (2019). Immunophenotyping of Acute Lymphoblastic Leukemia. In: McCoy, Jr, J. (eds) Immunophenotyping. Methods in Molecular Biology, vol 2032. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9650-6_16
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9650-6_16
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9649-0
Online ISBN: 978-1-4939-9650-6
eBook Packages: Springer Protocols